Luis Borges - 21 Mar 2023 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role
Chief Scientific Officer
Signature
/s/ Michael Diem, Attorney-in-Fact
Issuer symbol
IPSC
Transactions as of
21 Mar 2023
Net transactions value
-$179,128
Form type
4
Filing time
23 Mar 2023, 19:31:37 UTC
Previous filing
06 Feb 2023
Next filing
05 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IPSC Common Stock Options Exercise $65,524 +63,616 +145% $1.03 107,366 21 Mar 2023 Direct
transaction IPSC Common Stock Sale $239,870 -63,616 -59% $3.77 43,750 21 Mar 2023 Direct F1
transaction IPSC Common Stock Options Exercise $67,669 +65,698 +150% $1.03 109,448 22 Mar 2023 Direct
transaction IPSC Common Stock Sale $244,640 -65,698 -60% $3.72 43,750 22 Mar 2023 Direct F2
transaction IPSC Common Stock Options Exercise $227,558 +220,930 +505% $1.03 264,680 23 Mar 2023 Direct
transaction IPSC Common Stock Sale $55,369 -15,597 -5.9% $3.55 249,083 23 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IPSC Stock Option (right to buy) Options Exercise $0 -63,616 -18% $0.000000 294,080 21 Mar 2023 Common Stock 63,616 $1.03 Direct F3
transaction IPSC Stock Option (right to buy) Options Exercise $0 -65,698 -22% $0.000000 228,382 22 Mar 2023 Common Stock 65,698 $1.03 Direct F3
transaction IPSC Stock Option (right to buy) Options Exercise $0 -220,930 -97% $0.000000 7,452 23 Mar 2023 Common Stock 220,930 $1.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.57 to $3.79, inclusive.
F3 The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.